#potential - Techseriesinsight

June 16, 2025
PRNewswire
Biotechnology

Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining treatment paradigms through inflammation-targeted and resilience-driven therapies, today announced the successful completion of its first-in-human Phase 1 clinical trial evaluating HT-4253...

May 28, 2025
PRNewswire
Healthcare

Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors

Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today...

May 16, 2025
PRNewswire
Biotechnology

Genome & Company’s Skincare Brand UIQ Expands into North America with Official Amazon Brand Store Launch

Genome & Company, a global clinical-stage biotechnology firm, has officially launched its skincare brand UIQ (www.theuiq.com) on Amazon, the largest e-commerce platform in the United States. UIQ, renowned for its...

April 30, 2025
PRNewswire
Healthcare

Samaritas Foster Parents Share the Joy of Caring for Teens and Tweens

Samaritas, one of Michigan’s most trusted foster care agencies, is actively seeking empathetic adults to foster kids between the ages of eight and sixteen. These impressionable youth are at risk of...

April 15, 2025
PRNewswire
Biotechnology

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial...

April 11, 2025
PRNewswire
Blockchain Technology

Bybit Web3 Exclusive: BTC Staking with Lombard, up to 5% APY and Points Multipliers

Bybit, the world’s second-largest cryptocurrency exchange by trading volume, today announced a strategic initiative to expand access to BTC staking with Lombard Finance, the developer of LBTC, the leading staked BTC....

April 8, 2025
PRNewswire
Healthcare

Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis

Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the first patient has been dosed in its CLEAR-AD1 Phase 2b clinical trial of Zabalafin Hydrogel in Australia. The trial will evaluate...

April 4, 2025
PRNewswire
Biotechnology

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension of the PACIFIC trial investigating bexicaserin, in addition to new analyses from clinical trials and real-world...

April 1, 2025
PRNewswire
Biotechnology

Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team

Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) for cancers with a high unmet medical need, today announced two important Board changes...